Federated Hermes’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-119,425
| Closed | -$539K | – | 2254 |
|
|
2025
Q2 | $539K | Sell |
119,425
-34,028
| -22% | -$153K | ﹤0.01% | 1318 |
|
|
2025
Q1 | $680K | Buy |
153,453
+108,979
| +245% | +$633K | ﹤0.01% | 1217 |
|
|
2024
Q4 | $348K | Hold |
44,474
| – | – | ﹤0.01% | 1400 |
|
|
2024
Q3 | $585K | Hold |
44,474
| – | – | ﹤0.01% | 1292 |
|
|
2024
Q2 | $537K | Sell |
44,474
-91
| -0.2% | -$1.23K | ﹤0.01% | 1302 |
|
|
2024
Q1 | $725K | Buy |
44,565
+91
| +0.2% | +$1.23K | ﹤0.01% | 1240 |
|
|
2023
Q4 | $303K | Buy |
44,474
+43,549
| +4,708% | +$252K | ﹤0.01% | 1450 |
|
|
2023
Q3 | $5.04K | Buy |
+925
| New | +$5.39K | ﹤0.01% | 1882 |
|
|
2023
Q2 | – | Sell |
-63,956
| Closed | -$320K | – | 2235 |
|
|
2023
Q1 | $320K | Sell |
63,956
-63,579
| -50% | -$260K | ﹤0.01% | 1513 |
|
|
2022
Q4 | $622K | Buy |
+127,535
| New | +$927K | ﹤0.01% | 1290 |
|
|
2021
Q2 | – | Sell |
-93,597
| Closed | -$2.83M | – | 2350 |
|
|
2021
Q1 | $2.83M | Buy |
93,597
+71,445
| +323% | +$2.93M | 0.01% | 1002 |
|
|
2020
Q4 | $1.1M | Sell |
22,152
-87,000
| -80% | -$4.02M | ﹤0.01% | 1289 |
|
|
2020
Q3 | $4.19M | Buy |
109,152
+20,344
| +23% | +$810K | 0.01% | 776 |
|
|
2020
Q2 | $3.84M | Buy |
+88,808
| New | +$3.36M | 0.01% | 781 |
|
Other funds holding YMAB
Federated Hermes's YMAB Position: Q3 2025 in Review
Federated Hermes sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 119,425 shares — an estimated $539K sold.
Federated Hermes first reported a position in YMAB in Q2 2020 and held it in 14 quarters. The position peaked at $4.19M in Q3 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Federated Hermes reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Federated Hermes sold 119,425 Y-mAbs Therapeutics shares in Q3 2025, an estimated $539K.
- Federated Hermes first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 14 quarters.
- Federated Hermes's Y-mAbs Therapeutics position peaked at $4.19M in Q3 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.